Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2





Top > Articles > Allergy and Clinical Immunology  

Web Links
Sort By :
381. Resistance: New Data and Implications (Slides With Audio)




From The New York Course, Dr. Daniel R. Kuritzkes discusses antiretroviral approvals and agents in late-stage clinical development, including CCR5 antagonists, integrase inhibitors, and etravirine.
Medscape HIV/AIDS
Category:   Articles > Allergy and Clinical Immunology

Date Added: May 31, 2008 Hits: 0 Rating: 0.00 Votes: 0
Member Reviews Visitor Ratings Google PR

382. Interpreting Resistance: Guiding Principles (Slides With Audio)




Mark A. Wainberg, PhD, gives a masterclass on resistance to antiretroviral therapies in this presentation from the New York Course.
Medscape HIV/AIDS
Category:   Articles > Allergy and Clinical Immunology

Date Added: May 31, 2008 Hits: 0 Rating: 0.00 Votes: 0
Member Reviews Visitor Ratings Google PR

383. Nonnucleoside Reverse Transcriptase Inhibitors (Slides with Audio)




At the New York Course, Dr. Edwin DeJesus discusses recent additions to the antiretroviral armamentarium, specifically in the class of nonnucleoside reverse transcriptase inhibitors.
Medscape HIV/AIDS
Category:   Articles > Allergy and Clinical Immunology

Date Added: May 31, 2008 Hits: 0 Rating: 0.00 Votes: 0
Member Reviews Visitor Ratings Google PR

384. Integrase Inhibitors (Slides with Audio)




At the New York Course, Dr. Martin Markowitz discusses recent additions to the antiretroviral armamentarium, specifically in the class of integrase inhibitors.
Medscape HIV/AIDS
Category:   Articles > Allergy and Clinical Immunology

Date Added: May 31, 2008 Hits: 0 Rating: 0.00 Votes: 0
Member Reviews Visitor Ratings Google PR

385. Co-receptor Inhibitors (Slides with Audio)




At the New York Course, Dr. Roy M. Gulick discusses recent additions to the antiretroviral armamentarium, specifically co-receptor inhibitors in the class of entry inhibitors.
Medscape HIV/AIDS
Category:   Articles > Allergy and Clinical Immunology

Date Added: May 31, 2008 Hits: 0 Rating: 0.00 Votes: 0
Member Reviews Visitor Ratings Google PR

386. Designing Regimens for Experienced Patients (Slides With Audio)




Dr. Richard H. Haubrich discusses how to design regimens for experienced patients at HIV Management 2008: The New York Course, held April 25-26, 2008, in New York, NY.
Medscape HIV/AIDS
Category:   Articles > Allergy and Clinical Immunology

Date Added: May 31, 2008 Hits: 0 Rating: 0.00 Votes: 0
Member Reviews Visitor Ratings Google PR

387. Potency and Sustainability of Antiretroviral Regimens (Slides With Audio)




Dr. Eric S. Daar discusses the potency and sustainability of antiretroviral regimens at HIV Management 2008: The New York Course, held April 25-26, 2008, in New York, NY.
Medscape HIV/AIDS
Category:   Articles > Allergy and Clinical Immunology

Date Added: May 31, 2008 Hits: 0 Rating: 0.00 Votes: 0
Member Reviews Visitor Ratings Google PR

388. Update on Antiretroviral Toxicities (Slides With Audio)




Dr. Sharon L. Walmsley reviews the recent updates on antiretroviral toxicities at HIV Management 2008: The New York Course, held April 25-26, 2008, in New York, NY.
Medscape HIV/AIDS
Category:   Articles > Allergy and Clinical Immunology

Date Added: May 31, 2008 Hits: 0 Rating: 0.00 Votes: 0
Member Reviews Visitor Ratings Google PR

389. Curcumin Suppresses IgE-Mediated Allergic Response and Mast Cell Activation




Curcumin, which gives curry its yellow color, inhibits Syk kinase-dependent signaling events in mast cells in mice and might therefore be useful in the treatment of mast cell-related allergic diseases, according to a report by Korean and U.S. researchers in the May issue of the Journal of Allergy and Clinical Immunology. Reuters Health Information
Category:   Articles > Allergy and Clinical Immunology

Date Added: Jun 6, 2008 Hits: 0 Rating: 0.00 Votes: 0
Member Reviews Visitor Ratings Google PR

390. Omalizumab Cost-Effective for Severe Persistent Allergic Asthma




The anti-IgE antibody omalizumab is cost-effective for treating patients with severe persistent allergic asthma despite high-dose inhaled corticosteroid (ICS) plus a long-acting beta-2-agonist (LABA), according to a report in the June issue of Allergy. Reuters Health Information
Category:   Articles > Allergy and Clinical Immunology

Date Added: Jun 6, 2008 Hits: 0 Rating: 0.00 Votes: 0
Member Reviews Visitor Ratings Google PR

Pages: [<< First] [< Previous] 34 35 36 37 38 39 40 41 42 43 [Next >] [Last >>]

Category Jump :



Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS